|
Valoración de DCF de Soligenix, Inc. (SNGX)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Soligenix, Inc. (SNGX) Bundle
¡Agilice su análisis y aumente la precisión con nuestra calculadora DCF (SNGX)! Con datos reales de Soligenix, Inc. y suposiciones personalizables, esta herramienta le permite pronosticar, evaluar y evaluar (SNGX) al igual que un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.6 | 2.4 | .8 | .9 | .8 | .6 | .4 | .3 | .2 | .2 |
| Revenue Growth, % | 0 | -49.04 | -65.07 | 15.12 | -11.55 | -27.63 | -27.63 | -27.63 | -27.63 | -27.63 |
| EBITDA | -9.4 | -18.2 | -12.2 | -14.1 | -7.9 | -.6 | -.4 | -.3 | -.2 | -.2 |
| EBITDA, % | -202.06 | -772.47 | -1483.49 | -1486.56 | -935.58 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .2 | .2 | .2 | .1 | .0 | .1 | .0 | .0 | .0 | .0 |
| Depreciation, % | 3.84 | 8.18 | 18.25 | 14.47 | 0.78083 | 9.1 | 9.1 | 9.1 | 9.1 | 9.1 |
| EBIT | -9.5 | -18.4 | -12.4 | -14.2 | -7.9 | -.6 | -.4 | -.3 | -.2 | -.2 |
| EBIT, % | -205.89 | -780.66 | -1501.74 | -1501.02 | -936.36 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 5.4 | 18.7 | 26.0 | 13.4 | 8.4 | .6 | .4 | .3 | .2 | .2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.5 | .6 | .2 | .2 | .2 | .2 | .1 | .1 | .1 | .0 |
| Account Receivables, % | 31.6 | 23.94 | 29.45 | 23.11 | 23.25 | 26.27 | 26.27 | 26.27 | 26.27 | 26.27 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0.000043197328 | 0 | 0 | 0.000105383961 | 0 | 0.000029716258 | 0.000029716258 | 0.000029716258 | 0.000029716258 | 0.000029716258 |
| Accounts Payable | 2.7 | 2.1 | 2.9 | 3.9 | 1.1 | .5 | .4 | .3 | .2 | .1 |
| Accounts Payable, % | 59.08 | 90.27 | 354.93 | 407.39 | 132.39 | 89.87 | 89.87 | 89.87 | 89.87 | 89.87 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -0.65247 | -0.30291 | -1.43 | -1.38 | -0.000119138533 | -0.75269 | -0.75269 | -0.75269 | -0.75269 | -0.75269 |
| Tax Rate, % | 22.35 | 22.35 | 22.35 | 22.35 | 22.35 | 22.35 | 22.35 | 22.35 | 22.35 | 22.35 |
| EBITAT | -8.9 | -17.6 | -11.6 | -13.1 | -6.1 | -.6 | -.4 | -.3 | -.2 | -.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -7.5 | -17.1 | -10.3 | -12.1 | -8.8 | -1.0 | -.5 | -.3 | -.2 | -.2 |
| WACC, % | 5.95 | 5.99 | 5.94 | 5.9 | 5.45 | 5.84 | 5.84 | 5.84 | 5.84 | 5.84 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -5 | |||||||||
| Present Terminal Value | -4 | |||||||||
| Enterprise Value | -6 | |||||||||
| Net Debt | -5 | |||||||||
| Equity Value | -1 | |||||||||
| Diluted Shares Outstanding, MM | 0 | |||||||||
| Equity Value Per Share | -1.23 |
What You Will Get
- Comprehensive SNGX Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust discount rates, tax assumptions, revenue growth, and capital investments.
- Dynamic Calculations: Intrinsic value and net present value are computed in real-time.
- Scenario Testing: Explore various scenarios to assess Soligenix’s future potential.
- User-Friendly Interface: Designed for industry experts while remaining approachable for newcomers.
Key Features
- 🔍 Real-Life SNGX Financials: Pre-filled historical and projected data for Soligenix, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Soligenix’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Soligenix’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Obtain the comprehensive Excel file featuring Soligenix, Inc. (SNGX) financial data.
- Customize: Tailor your forecasts, including revenue growth, EBITDA %, and WACC.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and instantly compare the results.
- Make Decisions: Leverage the valuation outcomes to inform your investment strategy.
Why Choose This Calculator for Soligenix, Inc. (SNGX)?
- Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses tailored for Soligenix, Inc. (SNGX).
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios for Soligenix, Inc. (SNGX).
- Detailed Insights: Automatically computes Soligenix, Inc. (SNGX)'s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide a solid foundation for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on Soligenix, Inc. (SNGX).
Who Should Use Soligenix, Inc. (SNGX)?
- Investors: Gain insights into innovative biopharmaceutical solutions and make informed investment choices.
- Healthcare Analysts: Utilize comprehensive data to evaluate the potential of Soligenix's product pipeline.
- Consultants: Tailor presentations and reports on Soligenix's market strategies and clinical developments.
- Biotech Enthusiasts: Enhance your knowledge of the biopharmaceutical industry through Soligenix's advancements.
- Educators and Students: Leverage real-world case studies of Soligenix in academic discussions on biotechnology and pharmaceuticals.
What the Template Contains
- Pre-Filled DCF Model: Soligenix’s financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Soligenix’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.